title: Chronic co-administration of nicotine and methamphetamine causes differential expression of immediate early genes in the dorsal striatum and nucleus accumbens of rats.
abstract: Nicotine and methamphetamine (METH) cause addiction by triggering neuroplastic changes in brain reward pathways though they each engage distinct molecular targets (nicotine receptors and dopamine transporters respectively). Addiction to both drugs is very prevalent, with the vast majority of METH users also being smokers of cigarettes. This co-morbid occurrence thus raised questions about potential synergistic rewarding effects of the drugs. However, few studies have investigated the chronic neurobiological changes associated with co-morbid nicotine and METH addiction. Here we investigated the effects of these two drugs alone and in combination on the expression of several immediate early genes (IEGs) that are sensitive to drug exposures. Chronic exposure to either nicotine or METH caused significant decreases in the expression of fosb, fra1, and fra2 in the nucleus accumbens (NAc) but not in the dorsal striatum whereas the drug combination increased fra2 expression in both structures. Except for junB mRNA levels that were decreased by the three drug treatments in the NAc, there were no significant changes in the Jun family members. Of the Egr family members, NAc egr2 expression was decreased after nicotine and the drug combination whereas NAc egr3 was decreased after METH and the drug combination. The drug combination also increased striatal egr3 expression. The Nr4a family member, nr4a2/nurr1, showed increased striatal expression after all three drug treatments, while striatal nr4a3/nor-1 expression was increased by the drug combination whereas NAc nr4a1/nurr77 was decreased by nicotine and the drug combination. These observations suggest that, when given in combination, the two drugs exert distinct effects on the expression of IEGs in dopaminergic projection areas from those elicited by each drug alone. The significance of these changes in IEG expression and in other molecular markers in fostering co-morbid METH and nicotine abuse needs to be further evaluated.
authors.affiliation: Molecular Neuropsychiatry Research Branch, NIDA IRP, Baltimore, MD 21224, USA.
authors.forename: F
authors.initials: F
authors.lastname: Saint-Preux
authors.forename: L R
authors.initials: LR
authors.lastname: Bores
authors.forename: I
authors.initials: I
authors.lastname: Tulloch
authors.forename: B
authors.initials: B
authors.lastname: Ladenheim
authors.forename: R
authors.initials: R
authors.lastname: Kim
authors.forename: P K
authors.initials: PK
authors.lastname: Thanos
authors.forename: N D
authors.initials: ND
authors.lastname: Volkow
authors.forename: J L
authors.initials: JL
authors.lastname: Cadet
mesh_terms: D000818:Animals; D000697:Central Nervous System Stimulants / Q000008:administration & dosage; D003342:Corpus Striatum / Q000187:drug effects*; D005786:Gene Expression Regulation / Q000187:drug effects*; D017781:Genes, Immediate-Early / Q000187:drug effects*; D008297:Male; D008694:Methamphetamine / Q000008:administration & dosage; D009538:Nicotine / Q000008:administration & dosage; D018722:Nicotinic Agonists / Q000008:administration & dosage; D009714:Nucleus Accumbens / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012907:Smoking / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology; D019966:Substance-Related Disorders / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology
chemical_list: D000697:Central Nervous System Stimulants; D018722:Nicotinic Agonists; D008694:Methamphetamine; D009538:Nicotine
references.citation: Drug Alcohol Depend. 2008 Jan 11;93(1-2):63-71
references.pmid: 17961933
references.citation: Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11042-6
references.pmid: 11572966
references.citation: Trends Neurosci. 2011 Aug;34(8):411-20
references.pmid: 21764143
references.citation: PLoS One. 2012;7(3):e34236
references.pmid: 22470541
references.citation: Psychopharmacology (Berl). 2007 Feb;190(3):269-319
references.pmid: 16896961
references.citation: Psychopharmacology (Berl). 2009 Sep;206(1):51-60
references.pmid: 19506837
references.citation: Br J Pharmacol. 1995 Jan;114(2):454-60
references.pmid: 7881744
references.citation: Br J Pharmacol. 1992 Apr;105(4):849-56
references.pmid: 1504716
references.citation: Nat Neurosci. 2010 Sep;13(9):1128-36
references.pmid: 20711186
references.citation: Neuroscience. 1992 Jul;49(2):285-96
references.pmid: 1359451
references.citation: Eur J Pharmacol. 1997 Apr 23;325(1):13-20
references.pmid: 9151933
references.citation: Trends Mol Med. 2008 Aug;14(8):341-50
references.pmid: 18635399
references.citation: Psychopharmacology (Berl). 2011 May;215(2):353-65
references.pmid: 21229349
references.citation: J Pharmacol Exp Ther. 2005 Nov;315(2):872-8
references.pmid: 16040813
references.citation: Epigenetics. 2012 Feb;7(2):146-54
references.pmid: 22395464
references.citation: Brain Res Gene Expr Patterns. 2002 Jan;1(2):101-6
references.pmid: 15018806
references.citation: Synapse. 2001 Jul;41(1):40-8
references.pmid: 11354012
references.citation: Brain Res. 2010 Mar 8;1318:1-10
references.pmid: 20059987
references.citation: J Psychopharmacol. 2011 Feb;25(2):239-48
references.pmid: 19939874
references.citation: J Pharmacol Exp Ther. 1995 Jul;274(1):90-6
references.pmid: 7616454
references.citation: J Neurosci. 1996 Jul 1;16(13):4231-9
references.pmid: 8753884
references.citation: Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3245-55
references.pmid: 18640924
references.citation: J Neurosci. 2006 Mar 29;26(13):3584-8
references.pmid: 16571766
references.citation: Compr Psychiatry. 2006 May-Jun;47(3):215-20
references.pmid: 16635651
references.citation: J Toxicol Sci. 1999 Feb;24(1):55-62
references.pmid: 10073337
references.citation: Brain Res Brain Res Rev. 1998 Dec;28(3):370-490
references.pmid: 9858769
references.citation: N Engl J Med. 2010 Jun 17;362(24):2295-303
references.pmid: 20554984
references.citation: J Neurochem. 2003 Mar;84(6):1431-41
references.pmid: 12614343
references.citation: Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5764-8
references.pmid: 1631058
references.citation: Neuron. 2006 Oct 19;52(2):255-69
references.pmid: 17046689
references.citation: Nat Rev Neurosci. 2001 Oct;2(10):695-703
references.pmid: 11584307
references.citation: J Neurochem. 2004 Sep;90(5):1094-103
references.pmid: 15312165
references.citation: Pharmacol Biochem Behav. 1993 Sep;46(1):135-9
references.pmid: 7902980
references.citation: Subst Use Misuse. 2005;40(9-10):1539-55
references.pmid: 16048832
references.citation: Mol Pharmacol. 2009 Apr;75(4):938-46
references.pmid: 19144785
references.citation: Pharmacol Rev. 1995 Mar;47(1):133-78
references.pmid: 7784478
references.citation: PLoS One. 2010 Dec 13;5(12):e15643
references.pmid: 21179447
references.citation: J Addict Dis. 2002;21(1):21-34
references.pmid: 11831497
references.citation: J Recept Signal Transduct Res. 2004 Aug;24(3):165-205
references.pmid: 15521361
references.citation: Neuropsychopharmacology. 2006 May;31(5):941-55
references.pmid: 16123749
references.citation: Drug Metab Dispos. 1999 Dec;27(12):1448-55
references.pmid: 10570026
references.citation: Brain Res Mol Brain Res. 1994 Apr;23(1-2):1-13
references.pmid: 7913201
references.citation: J Neurosci. 2011 Nov 23;31(47):16941-8
references.pmid: 22114264
references.citation: Science. 1997 Jan 3;275(5296):83-6
references.pmid: 8974398
references.citation: Nature. 1998 Jan 8;391(6663):173-7
references.pmid: 9428762
references.citation: PLoS One. 2009 Nov 12;4(11):e7812
references.pmid: 19915665
references.citation: Brain Res Mol Brain Res. 2004 Dec 20;132(2):146-54
references.pmid: 15582154
references.citation: Drug Alcohol Depend. 2010 Jan 1;106(1):72-8
references.pmid: 19733448
references.citation: J Neurosci. 2009 Apr 1;29(13):4035-43
references.pmid: 19339599
references.citation: Sci Transl Med. 2011 Nov 2;3(107):107ra109
references.pmid: 22049069
references.citation: Neuropsychopharmacology. 2009 Oct;34(11):2430-41
references.pmid: 19571794
references.citation: Brain Res Mol Brain Res. 1993 Oct;20(1-2):91-100
references.pmid: 8255186
references.citation: J Pharmacol Exp Ther. 2012 Aug;342(2):335-44
references.pmid: 22562772
references.citation: Pharmacology. 1995 Feb;50(2):128-36
references.pmid: 7716176
references.citation: Neurosci Biobehav Rev. 2007;31(3):287-314
references.pmid: 17141870
references.citation: Biochem Pharmacol. 2009 Oct 1;78(7):744-55
references.pmid: 19523928
references.citation: Brain Res Rev. 2009 May;60(2):379-407
references.pmid: 19328213
references.citation: Harv Rev Psychiatry. 2005 May-Jun;13(3):141-54
references.pmid: 16020027